Friedmann W, Steffens J, Lobeck H
Onkologie. 1984 Dec;7(6):337-41. doi: 10.1159/000215476.
Metastases of 47 known prostatic carcinomas were subjected to the unlabelled immunoperoxidase-procedure to localise prostaticacid-phosphatase (PAP) and prostatic-specific antigen (PSA). In bone-marrow, lymph-node, lung and liver metastases PAP was found in 64% and PSA in 78%. There was no significant difference between the intensity of staining in primary and metastatic neoplasm. In poorly differentiated metastases of prostatic adenocarcinomas less intense staining for PAP and PSA was found. The data suggest that the demonstration of PAP and PSA is a practical and sensitive test for the prostatic origin of a clinically and histologically unclassifiable metastasis.
对47例已知前列腺癌转移灶进行未标记免疫过氧化物酶法,以定位前列腺酸性磷酸酶(PAP)和前列腺特异性抗原(PSA)。在骨髓、淋巴结、肺和肝转移灶中,64%发现有PAP,78%发现有PSA。原发肿瘤和转移肿瘤的染色强度无显著差异。在前列腺腺癌的低分化转移灶中,发现PAP和PSA的染色强度较低。数据表明,PAP和PSA的检测对于临床和组织学上无法分类的转移灶的前列腺来源是一种实用且敏感的检测方法。